Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Your RPS

'Urgent reform' to pharmaceutical care for people with learning disabilities needed, says RPS

Current system of care failing to deliver basic standards for patients, Society warns.

The pharmaceutical care of people with learning disabilities (pictured) is failing to deliver basic standards and needs urgent reform, including a greater role for pharmacists, the Royal Pharmaceutical Society (RPS) says.

Source: Shutterstock.com

One in six adults who have learning disabilities but no diagnosis of mental illness are prescribed antipsychotic drugs

The pharmaceutical care of people with learning disabilities is failing to deliver basic standards and needs urgent reform, including a greater role for pharmacists, the Royal Pharmaceutical Society (RPS) says.

A report published by Public Health England on 14 July 2015 found one in six adults with learning disabilities but no diagnosis of mental illness are prescribed antipsychotic drugs by GPs. Over half of patients with learning disabilities who are prescribed the drugs have no recorded diagnosis of a condition that these medications are designed to treat.

In a statement, Sandra Gidley, chair of the English Pharmacy Board of the RPS, says this situation is cause for “deep concern”.

“No one should be taking medicines unless there are clear, documented and reasoned explanations for their continued use,” she says. “The current system fails to deliver this fundamental standard of care for people with learning disabilities. Reform is urgently needed and we are determined to play our part in ensuring this happens.”

She says that although no research has been undertaken specifically on the physical health implications of long-term use of such drugs on people with learning disabilities, past studies in patients with schizophrenia and dementia showed “significantly increased risk of movement disorders, anticholinergic effects, stroke and death”.

Gidley adds: “We believe pharmacists could play a much bigger role in ensuring patient safety through regular person-centred medicines reviews, working in an integrated team with patient and their carers.”

NHS England is set to issue a “call to action” to reduce inappropriate prescribing of psychotropic drugs to people with learning disabilities.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069002

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The pharmaceutical care of people with learning disabilities (pictured) is failing to deliver basic standards and needs urgent reform, including a greater role for pharmacists, the Royal Pharmaceutical Society (RPS) says.

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.